Six years sep­a­rat­ed from a ra­bies vac­cine scan­dal, Chi­na’s Yisheng­Bio grabs $130M to go big in in­fec­tious dis­eases, can­cer

In an­oth­er boost to the glob­al vac­cine field, top in­vestors in Chi­na have hud­dled to­geth­er to in­ject $130 mil­lion in­to Bei­jing-based Yisheng­Bio.

Co-led by Ocean­pine and Or­biMed, the Se­ries B now gives the biotech an en­vi­able list of mar­quee do­mes­tic VCs: EightRoad, F-Prime Cap­i­tal, 3W Cap­i­tal, Hill­house Cap­i­tal, MSA Cap­i­tal, AI­HC, Epiphron Cap­i­tal, Su­per­string Cap­i­tal and Haitong In­ter­na­tion­al. The stand­out here is Ad­ju­vant Cap­i­tal, a pub­lic-health-mind­ed crew with ties to the Gates Foun­da­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER